MSB 12.1% 55.5¢ mesoblast limited

I suspect that was the EAP trial that finished some years ago....

  1. 3,702 Posts.
    lightbulb Created with Sketch. 1263
    I suspect that was the EAP trial that finished some years ago. The data from that was presented to the ODAC, including the step change after Mesoblast took over the trial. When the EAP started it was under the auspices of Osiris, why I searched for prochymal at the time.

    https://clinicaltrials.gov/ct2/show/NCT00759018?term=prochymal&cond=Graft-versus-host-disease

    Based on very occasional comments from Silviu I believe Mesoblast continued to supply remestemcel-L for quite some time after the EAP finished, like years. Definitely worth confirmation of what is happening now.

    I also did some comparison of the footprint remestemcel-L had across the US hospital system through various trials, seemed to be about 43 institutions.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
55.5¢
Change
0.060(12.1%)
Mkt cap ! $633.0M
Open High Low Value Volume
50.0¢ 59.0¢ 48.5¢ $16.88M 30.80M

Buyers (Bids)

No. Vol. Price($)
4 62700 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
56.0¢ 40000 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
55.5¢
  Change
0.060 ( 15.7 %)
Open High Low Volume
50.5¢ 59.0¢ 48.5¢ 11524458
Last updated 16.02pm 29/03/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.